T315I mutation in Ph-positive acute lymphoblastic leukemia is associated with a highly aggressive disease phenotype: three case reports.

Abstract excerpt

T315I mutation in BCR-ABL causes resistance to therapy with tyrosine kinase inhibitors (TKIs) in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL) cases. We report three cases of relapse accompanied by T315I mutation during rapid disease progression. Case 1 was a 64-year-old male. During chemotherapy, qPCR detected a decrease of BCR-ABL to 190 copies once, but this suddenly increased to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Fusion Proteins, bcr-abl
• Share to BCR gene